1. Kumar S, Harrison S, Cavo M, et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. 24th Congress of European Hematology Association; Amsterdam, Netherlands; June 13–16, 2019. 273254.
2. Patient need, drug development, and risk;Lancet Oncol,2019
3. Innovation in the pharmaceutical industry: new estimates of R&D costs;DiMasi;J Health Econ,2016
4. Multiple myeloma—translation of trial results into reality;Moreau;Lancet,2016
5. Approach to the treatment of multiple myeloma: a clash of philosophies;Rajkumar;Blood,2011